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This paper was to explore bullatacin-mediated multidrug-resistant cell apoptosis at extremely low concentration. To investigate
its precise mechanisms, the pathway of cell apoptosis induced by bullatacin was examined. Bullatacin causes an upregulation
of ROS and a downregulation of ΔΨm in a concentration-dependent manner in ABCB1-overexpressing KBv200 cells. In addition,
cleavers of caspase-9, caspase-3, and PARPwere observed following therelease of cytochrome cfrom mitochondriaafter bullatacin
treatment. However, neither cleavage of caspase-8 nor change of expression level of bcl-2, bax and Fas was observed by the same
treatment. Pretreating KBv200 cells with N-acetylcysteine, an antioxidant modulator, resulted in a signiﬁcant reduction of ROS
generation and cell apoptosis induced by bullatacin. Bullatacin-induced apoptosis was antagonized by z-LEHD-fmk, a caspase-9
inhibitor, but not by z-IETD-fmk, a caspase-8 inhibitor. These implied that apoptosis of KBv200 cells induced by bullatacin was
associated with the mitochondria-dependent pathway that was limited to activation of apical caspase-9.
Copyright © 2009 Yong-Ju Liang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Multidrug resistance (MDR) is now recognized as one of
the most common causes of failure in cancer chemotherapy.
The MDR phenotype renders cross-resistance to structurally
and functionally unrelated antitumor agents. This phe-
nomenon often causes overexpression of MDR1 gene that
encodes a 170-KD transmembrane glycoprotein named as P-
glycoprotein (P-gp, ABCB1) [1].
Importantly, in addition to its role as an eﬄux pump,
ABCB1 regulates programmed cell death mediated by
chemotherapeutic agents, serum starvation, UV irradiation,
as well as ligation of the cell surface death receptors Fas
and tumor necrosis factor (TNF) receptor. Johnstone et al.
[2] demonstrated that functional ABCB1 inhibited the
activation of caspase-8 and -3 following Fas ligation and this
inhibitory eﬀect could be reversed by ABCB1 antagonists,
such as speciﬁc anti-ABCB1 monoclonal antibodies. The
alterations in apoptotic pathways would confer MDR cell
resistance to conventional chemotherapeutic agents such as
doxorubicin and vincristine [3]. Therefore, ABCB1 may play
a dual role in regulating cell death induced by these stimuli
via (i) removing the toxins from the cell and (ii) inhibiting
the activation of caspases-8 and -3 but not caspase-9. So
it has been postulated that MDR cells were sensitive to
apoptosis induced by a mitochondria-dependent pathway.
Up to today, strategies aimed at reversing MDR have
principally focused on inhibition or modulation of ABCB1
activity. Many MDR modulators have been identiﬁed, some
undergoing clinical trials, but currently none is in clinical
use. Novel anticancer drugs with eﬃciency to MDR cells
present another important strategy for overcoming MDR.
Recently, extracts prepared from a variety of plants have
been demonstrated to possess the ability in triggering the
mitochondria-dependent apoptotic pathway [4].
Bullatacin, a compound with an adjacent bis-tetra-
hydrofuran ring structure of annonaceous acetogenins, iso-
lated from the plant family annonaceae, is a promising novel
leadcompoundofanticanceragents.Functionally,bullatacin
exhibits potent bioactivities via inhibiting the complex I of
mitochondria and the NADH oxidase of plasma membrane
in tumor cells and depletion of ATP levels [5]. Further-
more, the ubiquinone-linked NADH oxidase, constitutively
expressed in the cell membrane of cancer cells, but only2 Journal of Biomedicine and Biotechnology
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Figure 1: The structure of bullatacin (a), the overexpression of ABCB1 in KBv200 cells (b), equal amount of protein from various cells was
loaded for Western blot as description in Section 2; the cytotoxicity of bullatacin (c), VCR (d), paclitaxel (e) and Dox (f) in KBv200 and KB
cells. Cell survival was determined by MTT assay as described in Section 2. Data represent means and standard errors of at least a triplicate
determination.Journal of Biomedicine and Biotechnology 3
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Figure 2: Continued.4 Journal of Biomedicine and Biotechnology
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Figure 2: Apoptosis, ROS level and mitochondrial transmembrane potential (ΔΨm) were determined in KB or KBv200 cells after treatment
with bullatacin. (a) Apoptotic morphology of KB and KBv200 cells (×400) was observed by Hoechst 33258 staining. The experiments were
performed three times and a representative experiment is shown. (b) The apoptotic rates of KB and KBv200 cells were calculated with
identiﬁed apoptosis cells by Hoechst 33258 stain dividing to accounted all cells (more than 2000 cells) after treated with bullatacin for 48
hours. Data represented means and standard errors of at least a triplicate determination. (c) Apoptotic cells were detected with Annexin
V/PI after bullatacin treatment for 48 hours. The left-upper quadrant represents cells stained mainly by propidium iodide, while the right
bottom quadrant represents cells stained mainly by Annexin V (apoptotic cells). The top right quadrant represents cells stained by both
PI and Annexin V (secondary necrosis). The experiments were performed three times and a representative experiment is shown. (d) The
apoptotic rates of KB and KBv200 cells was examined with Annexin V/PI after treated with bullatacin for 48 hours. Data represented means
andstandarderrorsofatleastatriplicatedetermination.(e)ROSlevelsdetectioninKBv200cellsaftertreatmentwithbullatacinfor12hours.
Relative ROS levels were represented by the fold DCF intensity compared with untreated cells. The samples were duplicated and the data is
a representative of three experiments. (f) Assessment of ΔΨm collapse in KBv200 cells. The collapse of ΔΨm was indicated by a reduction of
DiOC6 intensity because the cells lost DiOC6 staining. Data represented means and standard errors of at least a triplicate determination.
transiently in that of normal cells, is also inhibited by
bullatacin [6]. Importantly, bullatacin has shown potential
high cytotoxicity in vitro and antitumor activity in vivo [6–
9]. However, it is not yet clear how bullatacin inhibits the
growth of 50% of grown MDR cancerous cells at extremely
low concentrations in vitro. Could bullatacin induce MDR
cell apoptosis? Which pathway of cell apoptosis induced
by bullatacin will be involved in? Further research on the
functioning of mitochondria will hopefully lead to a better
assessment for the applicability of bullatacin.
2.MaterialsandMethods
2.1. Materials. Bullatacin was isolated from the seed of the
Annona atemoya by Professor W.S. Chen (South China Insti-
tute of Botany, Chinese Academy of Sciences). Its structure
is shown in Figure 1(a). MTT, Hoechst 33258, Annexin V-
F I T Ca n dP Iw e r ep r o d u c t so fS i g m aC h e m i c a lC o .f r o m
Genewindows Co. (Guangzhou, China). Mouse monoclonal
antibodies(MAbs)againstcaspase-8(Ab-3),caspase-9(F-7),
and caspase-3 (E-8), as well as rabbit polyclonal antibody
against ABCB1 (MDR1), bcl-2 and bak were purchased
from Santa-Cruz Biotechnology (Santa Cruz, Calif, USA).
PARP (c-20) was purchased from Pharmingen (San Diego,
Calif, USA). Peroxidase-conjugated anti-mouse and anti-
rabbit IgG were purchased from Calbiochem (La Jolla, Calif,
USA).
2.2. Cell Lines and Cell Culture. The human epidermoid
carcinoma cell line KB and its vincristine-selected derivative
KBv200 overexpressing ABCB1 were obtained from Chinese
Academy of Medical Sciences, Beijing, and were cultured in
RPMI 1640 culture medium with 10% FBS at 37
◦C in the
presence of 5% CO2 [10].
2.3. Cytotoxicity Assay. The MTT assay was used to access
cytotoxicity as described [11]. Brieﬂy, cells were grown in 96-
wellplatesandvariousconcentrationsofdrugswereaddedto
the wells for 72 hours prior to being assayed. The IC50 values
and the degree of resistance were calculated as described in
[11].Journal of Biomedicine and Biotechnology 5
2.4. Apoptotic Cells Detected by Hoechst 33258 Dye. After
treatment with bullatacin for 48 hours, the cells were col-
lected, washed with PBS, ﬁxed with 10% paraformaldehyde
for 30 minutes, and incubated in Hoechst 33258 (30μg/mL)
at room temperature for 30 minutes. Nuclear morphology
was examined using ﬂuorescence microscopy. To calculate
the percentage of apoptotic cells, all cells from four random
microscopic ﬁelds at 400× magniﬁcation were counted [12].
2.5. Annexin V-FITC Labeling of Apoptotic Cell Membranes.
Annexin V and PI staining was performed using Apop-
NexinTM FITC Apoptosis Detection Kit (Chemicon, USA).
After treated with bullatacin of desired concentrations for 48
hours, both ﬂoating and attached cells were collected and
resuspended in 200μL1× binding buﬀer containing Annexin
V (1:50) and PI (40ng/sample) for 15 minutes at 37
◦C in the
dark. Then the numbers of viable, apoptotic, and necrotic
cells were quantiﬁed by ﬂow cytometer (Becton Dickinson,
USA) and analyzed by CellQuest software as described [13].
At least 10,000 cells were analyzed for each sample.
2.6. Preparation of Cytosolic Extracts. The cells were washed
with PBS for three times and collected by centrifugation at
500 × g for 10 minutes. The cell pellet was resuspended
in ice-cold cell extract buﬀer (20mM HEPES, pH 7.5, 10
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1
mM DTT, 250 mM sucrose, protease inhibitor mixture) and
i n c u b a t e df o r1h o u ra t4 ◦C. The lysates were then pestled
with 30 strokes using a homogenizer. Homogenates were
centrifuged at 12,000 ×gf o r5m i n u t e sa t4 ◦C. Supernatants
were collected and further centrifuged at 100,000 × gf o r3 0
minutes at 4◦C to obtain cytosol [13].
2.7. Immunoblot Analysis. The cells were treated with bul-
latacin. After treatment, whole-cell lysates were extracted
with lysis buﬀer containing 1% Triton-100, 50mM sodium
chloride, 50mM sodium ﬂuoride, 20mM Tris (pH 7.4),
1mM EDTA, 1mM EGTA, 1 mM sodium vanadate, 0.2mM
phenylmethylsulfonyl ﬂuoride, and 0.5% Nonidet P-40.
Westernblottingwascarriedoutasdescribedpreviously[13]
and the proteins were detected by the enhanced chemilumi-
nescence detection system (Amersham, Aylesbury, UK).
2.8. Reactive Oxygen Species (ROS) Detection. 2,7-Dic-
hlorodihydroﬂuorescein diacetate (DCFH-DA) was used as
ROScapturingreagentwiththemethoddescribedpreviously
[13, 14]. DCFH-DA was deacetylated intracellularly by
nonspeciﬁc esterase, and then furthered oxidized by ROS
to the ﬂuorescent compound 2,7-dichloroﬂuorescein (DCF).
Cells were incubated with 10μM DCFH-DA at 37
◦Cf o r1 5
minutes. DCF ﬂuorescence was detected by ﬂow cytometry.
2.9. Mitochondrial Transmembrane Potential Measurement.
ΔΨm was measured by ﬂow cytometry with the mito-
chondrial tracking ﬂuorescent compound 3,3 -dihexyl-
oxacarbocynine (DiOC6). Uptake and accumulation of
DiOC6 in the mitochondrion are driven by ΔΨm, therefore
the collapse of ΔΨm is reﬂected by reduction or loss of
DiOC6 staining. DiOC6 at 100nmol/L was added into the
cell culture for 15 minutes at 37
◦C and then monitored by
ﬂow cytometry with excitation wavelength at 488nm and
emission wavelength at 530nm [13, 15].
2.10. Caspase Assays. Activity assays of Caspase-8 and
Caspase-9 were performed with the ApoAlert Caspase-8
Colorimetric Assay and the Caspase-9 Fluorescence assay
kits (both from Clontech), respectively. Equal numbers of
control or bullatacin-treated cells were incubated in cell lysis
buﬀer for 10 minutes, centrifuged, and the supernatants
were incubated in reaction buﬀer that contained IETD-AFC
(speciﬁc substrate for Caspase-8) or LEHD-AMC (speciﬁc
substrate for Caspase-9) at 37
◦Cf o r1h o u r .T h ea c t i v i t y
was assayed using a spectrophotometer for Caspase-8 and a
ﬂuorometer for Caspase-9. The speciﬁc change of Caspase-
9 activity was conﬁrmed by the addition of the Caspase-
9 inhibitor LEHD-CHO before incubation with Caspase-9
substrate, in parallel experiments [16].
2.11. Statistical Analysis. All experiments were replicated at
least three times. Statistical analysis was done by Student’s t
test analyses. The signiﬁcance was determined at P<. 05.
3. Results
3.1. KBv200 Cells Are Resistant to Anticancer Drugs. KBv200
cell line is a classical multidrug-resistant human epidermoid
carcinoma cell line that upregulates ABCB1 (Figure 1(b)). To
determinetheresistantpropertyofKBv200cells,cytotoxicity
of anticancer drugs for KBv200 was compared with their
parental drug-sensitive KB cells. KB or KBv200 cells were
cultured in the presence of full-range concentrations of
anticancer drugs such as vincristine, paclitaxel, or doxoru-
bicin for 72 hours, and cell death was determined by MTT
assay.ThechemotherapeuticagentseﬀectivelykilledKBcells,
whereas KBv200 cells were resistant to the chemotherapeutic
agent-induced death (Figures 1(d), 1(e),a n d1(f)). KBv200
cells were approximately 62-, 70-, and 75-fold resistant to
vincristine, paclitaxel and doxorubicin compared with KB
cells, respectively.
3.2. Inhibition of Cell Growth by Bullatacin in KB and KBv200
Cells. Cytotoxic eﬀects of bullatacin on KB and KBv200
cells were measured to examine whether KB and KBv200
cells exhibit diﬀerent sensitivity to bullatacin. It exhibited
an inhibitory eﬀect of bullatacin on the proliferation of
both KB and KBV200 cells in a concentration-dependent
manner after a 72-hour treatment (Figure 1(c)). Similar
IC50 of bullatacin was observed in KB and KBv200 cells
(2.5±1.2nmol/Lv e r s u s2 .7±1.3nmol/L,P>. 05),suggesting
bullatacin is characterized by similar cytotoxicity to the two
cell lines.
3.3. Cell Apoptosis Induced by Bullatacin. MDR cells are
resistant to apoptosis induced by traditional anticancer
drugs. To examine whether ABCB1-positive cells failed to
undergo apoptosis induced by bullatacin, apoptosis was6 Journal of Biomedicine and Biotechnology
assessed by Hoechst 33258 staining. Treatment with bullat-
acin resulted in signiﬁcant apoptosis in both KB and KBv200
c e l l sw i t hc o n d e n s e da n df r a g m e n t e dn u c l e i( Figure 2(a)).
The apoptotic rate was concentration-dependent after the
treatment of 5, 10 and 20nmol/L bullatacin for 48 hours
(Figure 2(b)).
To further conﬁrm that bullatacin leads to apoptosis, KB
and KBv200 cells were stained with Annexin V-FITC and PI,
and subsequently analyzed by ﬂow cytometry. As indicated
by FCM analysis, the proportion of Annexin V-staining cells
was increased with concentration in bullatacin-treated cells
(Figure 2(c)); Annexin V-staining KB and KBv200 cells at
controlgroup,5,10and,20nmol/Lbullatacintreatinggroup
were 1.8% versus 1.5%, 11.4% versus 12.9%, 23.0% versus
24.9% and 48.1% versus 46.5%, respectively, (Figure 2(d)).
3.4. ROS Generation and Mitochondrial Transmembrane
Potential Loss Induced by Bullatacin. As we know, ABCB1
inhibited the receptor-dependent apoptotic pathway
(caspase-8 as an apical caspase). Did bullatacin induce cell
apoptosis via mitochondrial-dependent pathway (caspase-
9 as an apical caspase)? To examine the mechanism of
apoptosis in bullatacin-treated KBv200 cells, we determined
ROS by ﬂow cytometry. A concentration-dependent
increase of ROS formation was observed after treatment
with bullatacin of desired cocentrations for 12 hours
(Figure 2(e)).
The ΔΨm loss was measured with DiOC6,w h i c h
incorporates into mitochondria according to ΔΨm.A s
shown in Figure 2(f), ΔΨm of KBv200 cells decreased in
a concentration-dependent manner after administration of
bullatacin for 12 hours.
3.5. Bullatacin Induced Cytochrome C Release and Caspase-9
and -3 Activation in KBv200 Cells. Mitochondrial dysfunc-
tion induces cytochrome c (Cyt C) release from the mito-
chondria to the cytosol. Immunoblotting was performed to
test the release of Cyt C and the subsequent activation of
caspase-9 and -3. As shown in Figure 3(a), compared with
the control, the 15-kDa band representing for cytosolic Cyt
Cbecameclearat5nmol/Landfullydevelopedat20nmol/L,
implying that Cyt C was released from the mitochondrial
compartment to the cytosol in a concentration-dependent
manner after the treatment of bullatacin. The release of
Cyt C from the mitochondrial intermembrane space into
the cytosol may be a limiting factor in caspase-9 activation
and represents a central coordinating step in apoptosis. In
consistent with what we found, the inactive caspase-9 and
-3 precursors and PARP were cleaved in the presence of
bullatacin. However, inactive caspase-8 precursor was not
cleaved in the same condition (Figure 3(a)).
To conﬁrm whether bullatacin specially triggers apical
caspase-9 activation, activities of caspase-8 and -9 as well
as cell apoptosis were assayed after treatment of KBv200
cells with 10nmol/L bullatcin for 48 hours in the presence
or absence of caspase-8 inhibitor z-IETD-fmk and caspase-
9 inhibitor z-LEHD-fmk. As shown in Figures 3(c) and
3(d), a signiﬁcant increase of caspase-9 activity in KBv200
cells treated with bullatacin alone was detected (P<. 01).
In contrast, activation of caspase-8 was not observed in
the same condition (P>. 05). Interestingly, z-LEHD-
fmk blocked the activation of caspase-9 and cell apoptosis
induced by bullatacin, but z-IETD-fmk did not. These
suggested that caspase-9 and -3 were involved in bullatacin-
induced apoptosis of KBv200 cells.
Moreover, Bcl-2 and bax are associated with the
mitochondrial-dependent apoptosis, whereas Fas and Fas
ligand are involved in that of receptor-dependent cell
apoptosis. Treatment of KBv200 cells with bullatacin did not
causesigniﬁcantalterationintheexpressionofbcl-2,baxand
Fas (Figure 3(b)).
To study the role of ROS accumulation in the cyto-
toxicity of bullatacin toward KBv200 cells, we evaluated
the combined eﬀect of bullatcin and N-acetyl-l-cysteine
(NAC), an antioxidant molecule. The protective eﬀect of
NACagainstbullatacin-mediatedapoptosis wasalsoassessed
by measuring Annexin V. Compared with treatment of
10nmol/L bullatacin alone for 48 hours, ROS generation
and cell apoptosis signiﬁcantly decreased in KBv200 cells
pretreated with 1mmol/L NAC for 4 hours (Figures 4(a) and
4(b)).
4. Discussion
Conventionalcancerchemotherapyissigniﬁcantlylimitedby
tumor cells exhibiting MDR, caused by the overexpression
of integral membrane transporters, such as ABCB1 and
MDR-associated proteins (MRPs/ABCCs), causing decrease
of drug accumulation and cellular death. A novel strategy
was the development of new anticancer drug with eﬃcacy
to MDR cells. Annonaceous acetogenins such as bullatacin
and acetogenin 89-2 were potent anticancer agents not only
responsive for sensitive cells but also MDR cells in vitro and
in vivo [7–9, 17]. ATP depletion is the mode of action of
the annonaceous acetogenins, oﬀering a special advantage in
thechemotherapeutictreatmentofMDRtumorsundergoing
ATP-dependent mechanisms.
In consistence with our previous ﬁndings, bullatacin sig-
niﬁcantly inhibited cell proliferation and induced apoptosis
in KB and KBv200 cells. Chih et al. [18] reported most of the
bullatacin-induced death of human hepatocarcinoma 2.2.15
cell was due to apoptosis. In the present study, we found
that bullatacin could induce cell apoptosis not only in drug-
sensitive KB cells but also in MDR KBv200 cells.
In the mitochondrial-dependent apoptosis pathway, the
instability of mitochondria leads to the redistribution of
Cyt C into the cytosol, which initiates the formation of
the apoptosome and the sequential activation of caspase-9
and -3 [17, 19, 20]. The present study found ΔΨm loss and
Cyt C release into cytosol and the sequential activation of
caspase-9 and -3 in KBv200 cells treated with bullatacin.
Furthermore, caspase-9 inhibitor could particularly block
bullatacin-mediated cell apoptosis in KBv200 cells, but not
for caspase-8 inhibitor. These suggest that mitochondrial-
dependent pathway is involved in bullatacin-trigged MDR
cell apoptosis.Journal of Biomedicine and Biotechnology 7
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Figure 3: Eﬀect of bullatacin on the release of cytochrome C from mitochondrial, activation of caspases (caspase-9, -8 and -3) and cleavage
of PARP (a) and on the expression of bax, bcl-2 and Fas (b) in KBv200 cells. After incubation with bullatacin at desired concentrations for 48
h, the cellular proteins were subjected to western blot analysis. The experiments were performed three times and a representative experiment
is shown; (c and d) Eﬀect of bullatacin on capase-8 and -9 activation and apoptosis induction in KBv200 cells. KBv200 cells were incubated
for 12 hours at 37
◦C in the absence or presence of caspase inhibitors, at a concentration of 10μM, prior to their exposure to 10nmol/L
bullatacin. 48 hours later, capase-8 and -9 activities were examined as the description of Section 2. Data represented means and standard
errors of at least a triplicate determination.
Although the downstream events following the release
of Cyt C from the mitochondria have been characterized,
the early signal-initiating events that cause the instability of
mitochondriabybullatacinremainpoorlyunderstood.Thus,
our eﬀort was to examine the ROS generation that inﬂuences
the mitochondria function and ultimately elucidate its
mechanism of action in KBv200 cells. We found that treating
with bullatacin caused the production of ROS, followed by
mitochondrial membrane permeabilization and initiation of
the apoptotic cascade, including Cyt C release and caspases
activation. Moreover, NAC, an antioxidant agent, decreased
ROS generation and protected KBv200 cells from apoptosis
induced by bullatacin.
ABCB1, a pump excreting classic anticancer drugs from
the inside of MDR cells, inhibits the sequent activation of
caspase-8 and -3 [2], exhibiting an inhibition of apoptosis8 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀect of antioxidant molecules N-acetyl-l-cysteine (NAC) on ROS generation (a) and cell apoptosis (b) induced by bullatacin
in KBv200 cells. KBv200 cells pretreated with 1mmol/L NAC for 4 hours and then exposed to 10nmol/L bullatacin for 48 hours, ROS
generation and cell apoptosis were examined. The experiments were performed three times and a representative experiment is shown.Journal of Biomedicine and Biotechnology 9
induced by receptor-dependent pathway. Bullatacin could
generate ROS and trigger mitochondria-dependent apop-
totic pathway that is not inhibited by ABCB1.
In conclusion, while mitochondrial properties induced
by ROS were clearly altered during bullatacin-mediated
cell death, our results demonstrate that the mitochondrial-
dependent pathway is implicated in this cell apoptotic
process.
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